Zhenyu Xu Sells 10,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Insider sale: Zhenyu Xu sold 10,000 SOPHiA GENETICS shares at an average price of $8.91 for $89,100 under a pre-arranged Rule 10b5-1 plan. Xu retained 556,887 shares after the transaction.
• Recent performance: SOPH shares traded at $8.40, near their 52-week high of $8.98, with the stock up substantially from its 52-week low of $3.10. The company reported quarterly revenue of $23.31 million but missed EPS expectations and continues to post significant losses.
• Analyst outlook: Analysts have a consensus “Hold” rating with an average price target of $10.00; three analysts rate the stock a Buy, one a Hold and one a Sell.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 10,000 shares of the firm's stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $8.91, for a total value of $89,100.00. Following the completion of the sale, the insider directly owned 556,887 shares of the company's stock, valued at $4,961,863.17. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total value of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total value of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total value of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Stock Performance

Shares of SOPH traded up $0.26 during trading hours on Monday, hitting $8.40. The company's stock had a trading volume of 748,702 shares, compared to its average volume of 248,108. The company has a market cap of $704.72 million, a price-to-earnings ratio of -7.30 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The business has a 50 day simple moving average of $6.52 and a two-hundred day simple moving average of $5.45. SOPHiA GENETICS SA has a 52-week low of $3.10 and a 52-week high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS in the 4th quarter worth about $49,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth approximately $49,000. First Dallas Securities Inc. bought a new position in shares of SOPHiA GENETICS in the first quarter worth approximately $50,000. Quadrature Capital Ltd purchased a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SOPH. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright raised their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, SOPHiA GENETICS has a consensus rating of "Hold" and an average target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source